Fig. 1.

Consort flow chart of the ISPY COVID trial. Among the 172 participants who declined consent, the number and percentage of individuals who declined to sign consent after being randomised to a particular agent were: 7 (24%) for Razuprotafib, 16 (19.3%) for Apremilast, 10 (21.3%) for FamCox, 17 (14.9%) for CVC, 31 (30.4%) for IC14, 18 (15.7%) for Icatibant, 17 (29.8%) for Pulmozyme, and 42 (15.3%) for Control. The remaining 14 individuals who declined consent were randomised to other investigational arms that were started before the discontinuation of agents reported in this manuscript. Individuals that consented to Control arm were “shared” among investigational agent arms if they were randomised in a time epoch that included the active investigational agent.